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Abstract
Background: Levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), and D-dimer predict mortality in HIV patients
on antiretroviral therapy (ART) with relatively preserved CD4+ T cell counts. We hypothesized that elevated pre-ART levels of these
markers among patients with advanced HIV would be associated with an increased risk of death following the initiation of ART.
Methods: Pre-ART plasma from patients with advanced HIV in South Africa was used to measure hsCRP, IL-6 and D-dimer.
Using a nested case-control study design, the biomarkers were measured for 187 deaths and two controls matched on age,
sex, clinical site, follow-up time and CD4+ cell counts. Odds ratios were estimated using conditional logistic regression. In
addition, for a random sample of 100 patients, biomarkers were measured at baseline and 6 months following
randomization to determine whether ART altered their levels.
Results: Median baseline biomarkers levels for cases and controls, respectively, were 11.25 vs. 3.6 mg/L for hsCRP, 1.41 vs.
0.98 mg/L for D-dimer, and 9.02 vs. 4.20 pg/mL for IL-6 (all p,0.0001). Adjusted odds ratios for the highest versus lowest
quartile of baseline biomarker levels were 3.5 (95% CI: 1.9–6.7) for hsCRP, 2.6 (95%CI 1.4–4.9) for D-dimer, and 3.8 (95% CI: 1.8–
7.8)forIL-6. Theseassociationswere strongerfordeathsthatoccurred more proximal tothe biomarkermeasurements.Levelsof
D-dimer and IL-6, but not hsCRP, were significantly lower at month 6 after commencing ART compared to baseline (p,0.0001).
Conclusions: Among patients with advanced HIV disease, elevated pre-ART levels of hsCRP, IL-6 and D-dimer are strongly
associated with early mortality after commencing ART. Elevated levels of inflammatory and coagulation biomarkers may
identify patients who may benefit from aggressive clinical monitoring after commencing ART. Further investigation of
strategies to reduce biomarkers of inflammation and coagulation in patients with advanced HIV disease is warranted.
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Introduction
An estimated 5.21 million people were living with HIV and
AIDS in South Africa in 2009, more than in any other country [1].
It is estimated that in 2008 over 250,000 South Africans died of
AIDS [2]. Multiple clinical trials have clearly demonstrated that
combination antiretroviral therapy (ART) significantly reduces
morbidity and mortality in HIV infected patients [3–14].
Fortunately, it is estimated that the number of persons initiating
ART in sub-Saharan Africa has increased by nearly eight fold
since 2004 [15]. However, HIV-infected patients in developing
countries may have a higher mortality rate after commencing
antiretroviral therapy compared to patients in developed countries
[16,17]. Most notably, studies conducted in sub-Saharan Africa
demonstrate that mortality may be particularly high in the first
three months after commencing ART [18–20]. There are likely to
be a variety of causes for this increased risk, including immune
reconstitution syndrome, opportunistic infections due to incom-
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e24243plete immune recovery, and toxicities associated with ART [21–
23]. Predicting who has an increased short-term risk of mortality
after starting ART could lead to modified clinical management or
interventions that decrease mortality.
A nested case-control study from the clinical trial Strategies for
Management of Antiretroviral Therapy (SMART) investigated the
association of all-cause mortality and elevated levels of inflamma-
tory and coagulation biomarkers in HIV-infected patients with
CD4+ count .350 cells/mm
3 [24,25]. In this analysis from the
SMART study, the majority of participants were on ART at
baseline and most had HIV RNA levels #400 copies/mL. In this
population, high sensitivity C-reactive protein (hsCRP) interleu-
kin-6 (IL-6), and D-dimer measured at study entry were strongly
related to all-cause mortality. These findings from SMART
suggest that ongoing immune activation and disturbances in
coagulation occur even during successful suppression of HIV
replication. This may explain the findings from a growing body of
literature demonstrating the increased risk of all-cause mortality
and serious non-AIDS conditions such as cardiac, renal and
hepatic disease in HIV-infected patients, even those with
controlled viremia as compared to the general population [26–28].
Relatively little has been reported on the association of pre-
ART levels of inflammation and coagulation markers with
mortality in patients with advanced HIV disease [29]. The
primary purpose of this investigation was to assess in an ART-
naive group of patients with advanced HIV infection whether pre-
ART levels of inflammatory and coagulation biomarkers are
associated with mortality. In addition to those analyses, we also
assessed whether initiation of ART lowered levels of these
biomarkers, and compared pre-ART biomarker levels among
patients with early versus late HIV infection, and HIV uninfected
patients.
Methods
Study Population
Phidisa II was an HIV treatment study that enrolled 1,771
antiretroviral naı ¨ve HIV-infected participants at six clinical sites in
South Africa with CD4+ T cell counts ,200 cells/mm
3 (or ,14%
for patients post-splenectomy) and/or any history of or active
AIDS-defining illness and with hemoglobin .9 g/dL (.8 g/dL
for women), neutrophil count .500 cells/mm
3, platelet count
.250/uL, and serum liver transaminases below five times the
upper limit of normal [30]. Following randomization to one of
four initial ART regimens (figure 1), patients were seen monthly
for three months, and then every three months for physical
examination and laboratory studies, including measurement of
CD4+ T cell count and HIV RNA level. Phidisa I was an
epidemiologic study that followed HIV–uninfected individuals as
well as HIV-infected participants with CD4 cell counts over 200
cells/mm
3. Stored plasma specimens from participants in Phidisa I
and Phidisa II were used for the analyses reported here.
The South African National Defence (SANDF) Force Ethics
Committee and the National Institute of Allergy and Infectious
Diseases Intramural Institutional Review Board approved the
Phidisa I and Phidisa II protocols and their informed consent
documents which contained language on the use of stored
specimens as used in the current study. Written informed consent
was obtained from all participants whose samples and data were
used for this study.
Laboratory Assays
Two inflammatory markers, hsCRP and IL-6, and one marker
of coagulation, D-dimer, were prospectively chosen for these
analyses since they have been associated with all-cause mortality in
previous studies of patients with HIV infection. Assays for each of
the three biomarkers evaluated in this study were performed at a
single laboratory. Assays were performed using stored EDTA
plasma from PPT tubes as follows: hsCRP assays [COBAS Integra
(high sensitive); Roche; normal range ,1.0 mg/L] were per-
formed by Bio Analytical Research Corporation (BARC, Johan-
nesburg, RSA); D-dimer assays (Innovance; Dade Behring
Marburg GmbH; normal range ,0.5 mg/L) were performed by
Lancet Laboratories (Johannesburg, RSA); IL-6 assays (Quanti-
kine HS; R&D Systems; normal range 0.428–8.870 pg/ml) were
performed by Synexa (Cape Town, RSA). Hematology and serum
chemistry assays, CD4+ T cell count, and HIV RNA were all
measured by BARC.
Biomarker Studies
Three related studies were performed. First, a nested case-
control study of all-cause mortality was carried out to assess
whether hsCRP, IL-6, and D-dimer, in pre-ART plasma were
associated with mortality. Biomarker levels in each of the 187
patients who died in Phidisa II and who had baseline specimens
stored were compared with two controls matched on age (+/25
years), sex, follow-up time (+/2 3 months), clinic site (six sites) and
CD4+ T cell count (+/2 25 cells/mm
3). These variables were
chosen to match cases and controls for the following reasons: age
and CD4+ cell count were chosen because of their known
association with mortality; sex was chosen to be consistent with
other studies evaluating these biomarkers in HIV-infected patients;
and site was chosen to control for potential variations in type of
participant and nature of care. Second, to evaluate the effect of
initiation of ART on markers of inflammation and coagulation, D-
dimer, hsCRP and IL-6 were measured for a random sample of
100 study participants on plasma collected six months after
commencing ART and compared with levels measured pre-ART.
Third, since our cases and controls had advanced immunosup-
pression with CD4+ T cell counts below 200 cells/mm
3,w e
compared their baseline biomarker levels to a group with early
HIV infection (CD4+ cell counts of at least 200 cells/mm
3) as well
as an HIV negative group randomly drawn from participants in
Phidisa I. For these analyses, D-dimer, hsCRP and IL-6 were
determined for 80 HIV-infected patients with early HIV disease
and 80 participants without HIV infection.
Statistical Methods
Conditional logistic regression analyses for matched case-
control studies were used to study the associations of baseline
clinical variables and biomarkers with mortality. Biomarkers were
categorized into quartiles and were also considered as continuous
variables after log10 transformation. The following baseline
covariates were included in adjusted (multivariate) regression
analyses: HIV disease group (classified by history of tuberculosis,
AIDS, or AIDS-related symptoms, hemoglobin (#11.9 vs.
.11.9 g/dL), platelet count (#234 vs. .234/uL), aspartate
aminotransferase (#39.5 vs. .39.5 u/L) and white blood cell
count (#3.8 vs. .3.8610
9 cells/L). The above dichotomous
variables were broken at the median. To determine whether
associations with mortality varied for early and late deaths, the
deaths and controls were divided in two groups based on the
median survival time of the deaths (167 days). A Wald statistic was
used to evaluate the effects of a biomarker as a function of death
time. To assess the impact of ART on markers of coagulation and
inflammation, D-dimer, hsCRP and IL-6 levels were compared at
baseline and month six in a random sample of 100 patients.
Analysis of covariance was used to determine if the six-month
South Africa Predictors of Mortality
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randomized groups for continuous variables. A p-value less than
0.05 was considered as significant and all reported p-values are
two-sided.
Results
Study Population
In Phidisa II, the average age of participants was 35 years and
median CD4+ cell count at study entry for the overall Phidisa
cohort was 106 cells/mm
3. Over a median follow-up of 24.7
months 208 deaths occurred [30], of which 187 had baseline
plasma specimens available for analysis. Of those 187 deaths, 172
had two matched controls and 15 had one matched control for a
total of 359 controls. Table 1 shows the baseline characteristics for
deaths and matched controls. There was no significant difference
in baseline HIV load between cases and controls (p=0.66).
Median CD4+ cell count at study entry for the 187 deaths
included in these analyses was 39 cells/mm
3. Low body mass
index (BMI), CD4+ T cell count, and hemoglobin, as well as
elevated platelet count, aspartate aminotransferase (SGOT), and
white blood cell count were associated with death (p,0.05).
Baseline Biomarkers and All-Cause Mortality
Prior to starting ART, median hsCRP, D-dimer, and IL-6 levels
were all significantly elevated in the deaths compared to controls
(Table 2), and strong risk gradients for all-cause mortality were
evident for higher levels of all three biomarkers (Table 3). Baseline
levels of the three markers of inflammation and coagulation were
directly correlated. The Spearman rank correlations for CRP vs.
D-dimer was 0.353; CRP vs. IL-6 was 0.71; and D-dimer vs. IL-6
was 0.38 (all p,0.00001). A model with all three biomarkers was
therefore considered. After adjusting for HIV disease state,
hemoglobin, platelet count, aspartate aminotransferase, and white
blood cell count, the odds ratios (OR) of the log10 transformed
biomarkers associated with a one IQR higher level were: CRP HR
1.96 (p=0.02); D-dimer HR 2.22 (p=0.05); and IL-6 HR 1.12
(p=0.57). Thus, baseline levels of CRP and D-dimer remained
significantly correlated with mortality in this multivariate model.
Median baseline levels of all three biomarkers were significantly
greater for the early deaths (defined as those deaths occurring
before the median of all deaths: ,67 days of commencing ART)
compared to their respective controls: median baseline level of
CRP was 29.4 for early deaths vs. 3.4 in their controls, D-dimer
was 1.8 vs. 0.98, and IL-6 was 10.9 vs. 4.2 (all p,0.0001). Median
baseline level of CRP was also significantly elevated for late deaths
vs. their respective controls (6.7 vs. 3.8 respectively; p=0.007), in
contrast to those for D-dimer (1.2 vs. 1.0; p=0.07) and IL-6 (5.0
vs. 4.0; p=0.14) that were not significantly different. As shown in
Table 4 and 5, after log10 transformation, a one interquartile range
higher level of hsCRP was associated with an OR of 5.2 (95% CI
3.1–8.9) for early deaths versus 1.9 (1.2–2.8) for late deaths; a one
interquartile range higher level D-dimer was associated with an
OR of 14.0 (95% CI 5.1–38.3) for early deaths versus 2.5 (1.1–5.8)
Figure 1. Phidisa II Study Design and Flow Diagram for Case-Control Substudy.
doi:10.1371/journal.pone.0024243.g001
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was associated with an OR of 7.8 (95% CI 3.7–16.6) versus 1.7
(0.9–3.2) for late deaths. The interaction between biomarker levels
and log10 death time of cases was significant for each marker
(hsCRP, IL-6 and D-dimer) (p,0.01).
Differences in Biomarker Levels from Baseline to 6
Months after Commencing ART
In 100 randomly selected Phidisa II patients, mean log
transformed biomarker levels at month 6 after commencing ART
were significantly lower than baseline levels for D-dimer (20.122;
p,0.0001) and IL-6 (20.274; p,0.0001) but not for hsCRP
(20.044, SD 0.649; p=0.41). The changes did not differ by
randomization assignment. No significant correlations were seen
with change in CD4+ T cell count and changes in biomarker levels.
Comparison of Baseline Biomarker Levels for HIV
Uninfected Patients, and Patients with Early and
Advanced HIV Infection
Table 6 shows that HIV uninfected participants had signifi-
cantly lower baseline levels of all three biomarkers compared to
patients with advanced HIV infection (p=0.001 for hsCRP,
p,0.0001 for D-dimer, and p=0.01 for IL-6) after adjustment for
baseline covariates. Compared to patients with advanced HIV
infection, patients with early HIV infection had significantly lower
baseline levels of hsCRP (p=0.002) and D-dimer (p=0.001), but
they had significantly higher baseline levels of IL-6 (p=0.01).
Finally, compared to HIV-uninfected controls, baseline levels of
D-dimer and IL-6, but not hsCRP, were significantly elevated in
patients with early HIV infection (p=0.003 for D-dimer,
p,0.0001 for IL-6, p=0.71 for hsCRP).
Discussion
This is the first study to demonstrate that markers of
inflammation and coagulation measured immediately before
ART is initiated are strongly associated with all-cause mortality
in patients with advanced HIV-infection. In this case control
study, patients who died after commencing ART had significantly
elevated levels of D-dimers, hsCRP and IL-6 compared to
matched controls, and strong risk gradients were observed for
increasing levels of all three biomarkers. In addition, elevated
baseline levels of inflammatory markers were more predictive of
early mortality than late mortality after ART initiation. This
association persisted in analyses that considered stage of HIV
disease, hemoglobin, aspartate aminotransferase, platelet and
white blood cell count. These findings suggest that HIV-induced
activation of inflammatory and coagulation pathways in late-HIV
infection have an adverse affect on mortality.
Table 1. Median Baseline Characteristics of Deaths and Matched Controls.
Deaths (n=187) Controls (n=359) p-value
a
Age (25
th,7 5
th %ile) 35 (32, 39) 35 (32, 38) NA
Sex (% female) 31 31 NA
BMI (kg/m
2)( 2 5
th,7 5
th %ile) 20.5 (18.3, 23.4) 22.3 (19.5, 25.7) 0.0001
CD4+ count (cells/mm
3)( 2 5
th,7 5
th %ile) 39 (9, 102) 42 (14, 110) NA
Log10 HIV RNA (25
th,7 5
th %ile) 5.29 (4.92, 5.56) 5.25 (4.87, 5.61) 0.68
Hepatitis B Surface Antigen (% positive) 8.6 5.3 0.11
Creatinine (mmol/L) (25
th,7 5
th %ile) 70 (59, 86) 72 (61, 84) 0.18
Hemoglobin (g/dL) (25
th,7 5
th %ile) 11.2 (9.7, 12.5) 12.2 (11, 13.6) ,0.0001
Platelet (610
9/L) (25
th,7 5
th %ile) 264 (185, 334) 224 (174, 284) 0.0003
SGOT (IU/L) (25
th,7 5
th %ile) 42 (31, 60) 37 (29, 54) 0.04
SGPT (IU/L) (25
th,7 5
th %ile) 31 (22, 52) 29 (21, 44) 0.18
WBC count (610
9/L) (25
th,7 5
th %ile) 4.1 (3.1, 6.1) 3.6 (2.8, 4.7) ,0.0001
ap-value obtained from univariate conditional logistic model. NA=not applicable as characteristic was a matching factor.
doi:10.1371/journal.pone.0024243.t001
Table 2. Baseline levels of hsCRP, IL-6 and D-dimer for Deaths and Matched Controls.
Biomarker Deaths (N=187) Median Controls (N=359) Median Difference in log10 levels between Cases and Control p-value
a
(25
th,7 5
th %ile) (25
th,7 5
th %ile) (SE)
hsCRP (ug/ml) 11.25 3.60 0.30 ,0.0001
(2.90, 51.90) (1.50, 11.30) (0.07)
D-dimer (ug/ml) 1.41 0.98 0.14 ,0.0001
(0.89, 2.82) (0.65, 1.60) (0.03)
IL-6 (pg/ml) 9.02 4.20 0.22 ,0.0001
(3.24, 18.66) (1.82, 8.13) (0.05)
ap-value obtained from a conditional logistic model with a single covariate corresponding to log10 transformed biomarker level.
doi:10.1371/journal.pone.0024243.t002
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e24243In our cohort of 100 random Phidisa II patients who initiated
ART, IL-6 and D-dimer levels significantly decreased at month 6,
whereas hsCRP did not. This association between IL-6 and D-
dimer is consistent with other studies including HIV-infected as
well as uninfected patients. [25,29–33]. Also, whereas positive
correlations were found with HIV viral load and hsCRP and D-
dimer levels, a correlation did not exist between HIV viral load
and IL-6 levels. This suggests that, in this population with
advanced HIV infection, the pathway that leads to elevated IL-6
levels during HIV infection may be different than the pathway
leading to elevations of other inflammatory biomarkers such as
hsCRP. Other studies are needed to confirm this finding.
A study of inflammatory and coagulation biomarkers in HIV-
infected patients in the SMART trial also demonstrated that
baseline IL-6 and D-dimer levels were strongly related to all-cause
mortality [24,25]. Although the same biomarker assays were used
in the SMART and our Phidisa II analyses, any comparison of
biomarker levels between these studies must be made with a
number of caveats: plasma from PPT was used in our study
whereas plasma from EDTA tubes was used in SMART, the
assays were performed at different laboratories, and there were
differences in sample processing timelines (specimens in Phidisa II
may have taken up to 24 hours to arrive in the laboratory for
processing). With these caveats in mind, median baseline
biomarker levels appear to be considerably higher in the Phidisa
II mortality cases compared to those in SMART (hsCRP=11.25
vs. 4.26 ug/ml; D-dimer=1.41 vs. 0.49 ug/ml; IL-6=9.02 vs.
3.8 pg/ml, respectively). This is likely due to the fact that the
patient populations enrolled in these studies were notably different.
The SMART study population was relatively healthy and did not
have advanced HIV disease; at baseline, the majority of
participants were on ART and had a relatively high CD4+ T
cell count [median=545 (25
th,7 5
th percentile=408, 693)]. In
contrast, our study population was not on ART and had advanced
HIV disease with low CD4+ T cell counts [median=39 (25
th,7 5
th
percentile=9, 102)]. This supports the hypothesis that advanced
immunosuppression in the context of unsuppressed HIV replica-
tion leads to an activation of inflammatory and coagulation
pathways and, subsequently, increases mortality.
We also examined levels of hsCRP, IL-6 and D-dimer among
HIV-uninfected patients, and patients with early and late HIV
infection. In general, uninfected patients had lower levels of these
biomarkers compared to patients with early disease, who in turn
had lower levels compared to those patients with late disease,
except for IL-6. This finding is consistent with other studies
demonstrating that, compared with those who are HIV-uninfect-
ed, HIV-infected individuals have higher levels of inflammatory
and coagulation markers [30].
A limitation to our study is that a definitive cause of death could
not be established for all mortality cases in Phidisa II. It is known
that 37 of the 208 deaths in Phidisa II followed a confirmed or
probable AIDS event, and tuberculosis was the most common
AIDS event observed in that trial. Nevertheless, analyses of the
relationship between biomarker levels and cause of mortality could
Table 6. Baseline Levels of hsCRP, IL-6 and D-dimer for HIV Uninfected Participants, and Participants with Early and Advanced HIV
Infection.
HIV uninfected (n=80) Early HIV infection* (n=80) Advanced HIV infection** (n=100)
Median Baseline Characteristics
Age 37 38 36
(25
th,7 5
th %ile) (33, 42) (35, 40) (33, 39)
Sex (% female) 31 31 35
CD4 + count (cells/mm3) NA 546 110
(25
th,7 5
th %ile) NA (409, 709) (58, 175)
HIV RNA NA 4,025 148,000
(25
th,7 5
th %ile) NA (1,036, 27,250) (64,900, 304,000)
Biomarker Levels (median; 25
th,7 5
th %ile)
HIV uninfected Early HIV infection* - No ART Advanced HIV infection* - No ART Intergroup Comparisons
Groups p-value***
hsCRP 2.35 (0.9, 7.3) 3.05 (1.2, 6.2) 4.30 (1.95,12.3) HIV negative vs. Early HIV 0.706
HIV negative vs. Late HIV 0.001
Early HIV vs. Late HIV 0.002
D-Dimer 0.52 (0.35, 0.7) 0.63 (0.43, 0.93) 0.86 (0.57,1.46) HIV negative vs. Early HIV 0.003
HIV negative vs. Late HIV ,0.0001
Early HIV vs. Late HIV 0.001
IL-6 1.59 (1, 2.34) 4.99 (1.5, 12.5) 2.61 (1.42, 5.23) HIV negative vs. Early HIV ,0.0001
HIV negative vs. Late HIV 0.01
Early HIV vs. Late HIV 0.01
NA=not applicable.
*CD4+ T cell count .350 cells/ml.
**CD4+ T cell count #200 cells/mL (or ,14% for patients post-splenectomy) and/or any history of or current AIDS defining illness and with hemoglobin .9g / d L( .8g /
dL for women), neutrophil count .500 cells/mL, platelet count .250/uL, and serum liver transaminases below five times the upper limit of normal.
***Comparisons between the different groups are adjusted for age, sex and BMI.
doi:10.1371/journal.pone.0024243.t006
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e24243not be performed. Another limitation is that other potential
confounding variables that may affect biomarker levels, such as
smoking and hepatitis C status, were not collected and could not
be adjusted for in our analyses.
In summary, among patients with advanced HIV disease,
elevated pre-ART levels of hsCRP, IL-6 and D-dimer are strongly
associated with early mortality after commencing ART. While the
reasons for the increased risk are not fully understood, interven-
tions other than ART that might decrease levels of inflammatory
and coagulation markers warrant investigation. Until such
interventions are found, more aggressive clinical monitoring may
be warranted in patients with elevated biomarkers after com-
mencing ART. Further studies are warranted to understand the
underlying pathophysiology leading to these elevations in
biomarker in order to develop interventions that may improve
clinical outcomes in HIV infected patients starting ART.
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